We also advocate for the use of anemia-directed agents such as erythropoietin and analogs (in patients with endogenous erythropoietin < 125 units/L), danazol, or luspatercept in combination with ruxolitinib to try to maintain ruxolitinib dose intensity rather than reduce the dose of ruxolitinib. Here, EPO is linked to anemia (phenotype).